No connection

Search Results

INDV vs TMDX

INDV
Indivior Pharmaceuticals, Inc.
NEUTRAL
Price
$30.54
Market Cap
$3.82B
Sector
Healthcare
AI Confidence
85%
TMDX
TransMedics Group, Inc.
BULLISH
Price
$113.13
Market Cap
$3.91B
Sector
Healthcare
AI Confidence
75%

Valuation

P/E Ratio
INDV
18.62
TMDX
23.28
Forward P/E
INDV
8.87
TMDX
30.71
P/B Ratio
INDV
-38.95
TMDX
8.19
P/S Ratio
INDV
3.08
TMDX
6.45
EV/EBITDA
INDV
10.01
TMDX
29.09

Profitability

Gross Margin
INDV
84.02%
TMDX
59.92%
Operating Margin
INDV
37.15%
TMDX
13.23%
Profit Margin
INDV
16.95%
TMDX
31.43%
ROE
INDV
--
TMDX
54.24%
ROA
INDV
19.22%
TMDX
7.25%

Growth

Revenue Growth
INDV
19.7%
TMDX
32.2%
Earnings Growth
INDV
376.2%
TMDX
1188.1%

Financial Health

Debt/Equity
INDV
--
TMDX
1.1
Current Ratio
INDV
0.71
TMDX
7.14
Quick Ratio
INDV
0.49
TMDX
6.41

Dividends

Dividend Yield
INDV
--
TMDX
--
Payout Ratio
INDV
0.0%
TMDX
0.0%

AI Verdict

INDV NEUTRAL

INDV presents a stark contrast between operational excellence and financial fragility, highlighted by a weak Piotroski F-Score of 2/9. While the company exhibits explosive earnings growth (376% YoY) and trades significantly below its intrinsic value of $48.38, its balance sheet is highly distressed with a negative Price/Book ratio of -38.95 and a Current Ratio of 0.71. The forward P/E of 8.87 suggests an attractive valuation for growth, but the underlying solvency risks prevent a bullish rating. The investment thesis relies entirely on continued high-margin growth to offset structural financial weaknesses.

Strengths
Exceptional gross margins (84.02%) and operating margins (37.15%)
Explosive YoY earnings growth of 376.20%
Strong earnings track record with 3/4 recent quarters beating estimates
Risks
Severe financial health warning indicated by Piotroski F-Score of 2/9
Negative shareholders' equity as evidenced by Price/Book of -38.95
Liquidity risk with a Current Ratio (0.71) and Quick Ratio (0.49) well below 1.0
TMDX BULLISH

TMDX exhibits a stable financial health profile with a Piotroski F-Score of 4/9 and exceptional liquidity (Current Ratio 7.14). While the Graham Number ($38.85) suggests significant overvaluation from a defensive standpoint, the growth-based intrinsic value of $143.37 indicates the current price of $113.13 is an attractive entry point for growth investors. The company has successfully transitioned from consistent losses to explosive earnings growth and high profitability (ROE 54.24%). Despite bearish insider sentiment and technicals, the fundamental trajectory and analyst consensus remain strongly positive.

Strengths
Explosive earnings growth (YoY 1188.10%) reflecting a successful pivot to profitability
Exceptional liquidity with a Current Ratio of 7.14 and Quick Ratio of 6.41
Strong profitability metrics including a 31.43% profit margin and 54.24% ROE
Risks
Bearish insider activity with 9 sell transactions and 0 buys in the last 6 months
Technical trend is currently 0/100, indicating strong short-term bearish momentum
High Price-to-Book ratio (8.19) suggests a premium valuation

Compare Another Pair

INDV vs TMDX: Head-to-Head Comparison

This page compares Indivior Pharmaceuticals, Inc. (INDV) and TransMedics Group, Inc. (TMDX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile